Concepedia

Basiliximab plus low‐dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation

R.K Kode, Kosunarty Fa, Shoaib Chowdhury, Karthik Ranganna, Billie Fyfe, Susan Stabler, A.M Damask, M.R. Laftavi, Anil Mysore Kumar, O. Pankewycz

Clinical Transplantation · 2003 · 21 citations · 24 references

DOI

Abstract

Compared with OKT3 induction therapy, the combination of early low-dose cyclosporin and basiliximab is steroid sparing, effective, well tolerated and relatively safe.

References

24

The Banff 97 working classification of renal allograft pathology

Lorraine C. Racusen, Kim Solez, Robert B. Colvin et al. · Kidney International · 1999 · 3K citations

Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients

Lode J. Swinnen, Maria Rosa Costanzo‐Nordin, Susan G. Fisher et al. · New England Journal of Medicine · 1990 · 949 citations

, , +20

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

Björn Nashan, Richard H. Moore, P L Amlot et al. · The Lancet · 1997 · 761 citations

, , +10

Cardiovascular disease after renal transplantation.

B L Kasiske, Carlos Guijarro, Ziad A. Massy et al. · Journal of the American Society of Nephrology · 1996 · 673 citations

, , +18

REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2

Barry D. Kahan, P. R. Rajagopalan, Michael Hall · Transplantation · 1999 · 482 citations